Fritextsökning
Artiklar per år
Innehållstyper
-
The vaccine has saved 94 million lives – but measles is spreading again
A disease we once believed belonged to the past is now resurging in both Europe and the United States. In the shadow of growing skepticism and declining vaccination coverage, measles – which has claimed millions of lives throughout history – is making a comeback.
-
Canada approves leqembi as global alzheimer’s drug race heats up
Leqembi has secured approval in Canada, further consolidating its global lead among disease-modifying Alzheimer’s therapies. The antibody is now authorized in 15 major markets — one more than its closest rival, Eli Lilly’s Kisunla.
-
Swedish life science is growing – but capital is not keeping up
The number of employees and companies in Swedish life science is increasing and the sector is more equal than many other sectors. But investments in unlisted companies are weak.
-
A cluster contribution to European life science innovation and competitiveness?
-
Heart Monitoring in Breast Cancer – Essential or Excessive?
Papakonstantinou is working to refine how doctors identify which patients truly need intensive follow-up.
-
Billion-Dollar Deal Sends BioArctic Soaring
Swedish Alzheimer-focused company BioArctic has entered into a licensing collaboration with Novartis regarding a technology aimed at enhancing efficient drug delivery to the brain. The BioArctic stock surged significantly following the announcement.
-
Wegovy approved in the U.S. for treatment of liver disease
The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Novo Nordisk’s drug Wegovy to treat the serious liver condition known as MASH. The decision strengthens the company’s position in the field of metabolic diseases.
-
FDA approves Gilead’s HIV injection: “Historic day”
Gilead Sciences’ preventive HIV drug, lenacapavir, was approved on Wednesday by the U.S. Food and Drug Administration (FDA), sparking new hope for finally breaking the transmission chain of a virus that affects 1.3 million people annually.
-
Kraftig viktnedgång i nya Novo Nordisk-studier
Två aktuella läkemedelsstudier från Novo Nordisk visar betydande viktminskning hos personer med fetma utan diabetes. Wegovy och det nya läkemedlet amycretin visar båda på över 20 procents viktminskning i kliniska studier.
-
The race between new alzheimer’s drugs Kisunla and Leqembi heats up
Kisunla or Leqembi? The rivalry between Eli Lilly and Bioarctic is intensifying. Where one drug gains approval, the other falls behind. Here's a look at the markets where these competing treatments are currently available.
-
Venomaid's rapid test aims to find the right snake bite treatment
Every six seconds, someone on our planet suffers a snake bite, and each time, a race against the clock begins. What kind of snake was it, and which antivenom can help? Danish company Venomaid Diagnostics is working hard to develop solutions to a problem that claims countless lives, especially in tropical countries.
-
Astra Zeneca faces potential multimillion-dollar fines in China
Astra Zeneca could be forced to pay up up to $8 million in fines for allegedly unpaid import duties in China, as the company seeks to rebuild trust following earlier controversies.
-
Mikael Kubista back with new venture after turbulent exit
from us. They followed up by showering us with lawsuits,” he says.
-
New moves around Nykode's management – withdrawal of resignations
Norwegian Nykode Therapeutics is reinstating members of the management team who previously announced their resignations.
-
FDA plans to replace animal testing with AI – “Paradigm shift”
The requirement for animal testing in drug development will be phased out and replaced by AI, according to an announcement by the FDA. The decision has been met with skepticism from the National Association for Biomedical Research.
-
Several departures at the top at Nykode
Members of both the management and the board are leaving the Norwegian biotech company Nykode.
-
A tiny animal with great importance
From the mythical Ganges River to the less sacred, but considerably cleaner waters in KI's aquariums in Solna. The little zebrafish has made an unconscious career – as an increasingly important model organism in medical research.
-
Who pays for Rebecca Doe – and all of us?
Anna Törner on how easily we get used to the idea that healthcare is free - when it really is about how and who pays for it
-
The art of successful licensing – “A lot has to align”
Sharp research, strong data and a high level of innovation are all very good, but more than that is required to achieve the goal of many biotechnology companies: to succeed with a licensing deal.
-
Ukraine war fuels rise of totally resistent bacteria
War-torn Ukraine is not just suffering from hostile attacks from a foreign aggressor, but also from the threat of a totally resistant and contagious bacteria.
-
Security flaw in Swedish breast cancer screening software – woman passed away
A lack of safeguard in Sectra's software led to a woman with breast cancer receiving an incorrect diagnosis. She later passed away. The software is used in 20 out of 21 regions in Sweden. It is also used in neighbouring Nordic countries. “Extremely serious,” says the Sectra CEO to Medtech Magazine.
-
Developing rapid diagnostics for sepsis – “Every hour counts”
Finding the right antibiotic in the right dose – with an ultra-fast analysis method. Gradientech's product solution is currently used in routine diagnostics at several hospitals in Europe – and the next target is the US market.
-
Health politician Lina Nordquist: ”I find it hard to be idle”
She is the pharmacist and researcher who grew tired of the breakthroughs that never materialised and knowledge that never seemed to reach patients, so she decided to make a change from within. Life Science Sweden meets Lina Nordquist, Member of Parliament for the Liberals and their spokesperson on healthcare policy, to have a conversation about reality, politics, and the need for writing.
-
Government apoints new experts to medicine and health council
Johanna Fälting, Head of Research at BioArctic, and physician Markus Lingman have been appointed as new members of the Swedish Research Council’s Subject Council for Medicine and Health.